Clinical Trial Update: Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing panitumumab-IRDye800 imaging against sentinel node biopsy and selective neck dissection for identifying metastatic lymph nodes in head a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Panitumumab-IRDye800

Snippet

Sponsor: Eben Rosenthal | Conditions: Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Status: COMPLETED | Results posted: 2022-11-10